ALFA FinderBSE filing, NSE: COHANCE. Summary written from the filing by ALFA Finder's alert engine.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹463.50
- Market cap
- ₹17,735 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 374.4×Sector 43.4×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Investor Presentation: Key Takeaways
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.
Cohance Lifesciences Q2 FY27 Results: Net Profit ₹2.3 Cr, Down 96.5% YoY
Cohance Lifesciences Ltd reported revenue from operations of ₹476.6 Cr (-14.2% YoY) and net profit of ₹2.3 Cr (-96.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹2.3 Cr · -96.5% YoY
Other capital structure change announcements
All →Bajaj Finance Capital Structure Change
Bajaj Finance's Special Committee opened its Rs 11,700 Crore QIP and approved the placement document on 11 November 2026. Equity shares will be issued subsequently under the shareholder-approved plan.
- Value
- ₹11,700 Cr
DCW Capital Structure Change
DCW Ltd bought back 2,00,000 shares on NSE on 11 November 2026 for about Rs.0.96 Crore at an average Rs.47.84. Cumulative buyback stands at 9,05,458 shares.
- Value
- ₹0.96 Cr
Bajaj Finance Capital Structure Change
Bajaj Finance's QIP committee opened its equity QIP on November 11, 2026. It fixed the floor price and approved the preliminary placement document.
V2 Retail Capital Structure Change
Motilal Oswal mutual fund schemes sold 39.21 lakh V2 Retail shares, cutting their holding from 6.00% to 4.92%. The disposal was executed through market transactions on November 6, 2026.
IIFL Finance Capital Structure Change
IIFL Finance's board approved an alteration of authorised share capital. The shareholder vote is set for 4 December 2026.
Bajaj Finserv Capital Structure Change
Bajaj Finserv completed subscription to Rs. 1,450 Crore of warrants issued by subsidiary Bajaj Finance. The completion follows a board-approved Rs. 5,800 Crore preferential issue.
- Value
- ₹1,450 Cr